This week we are going to discuss a neurological auto-immune condition that affects older patients but can even affect younger patients—Generalized Myasthenia Gravis. Unlike demyelinating diseases of ...

Findings showed nipocalimab plus standard of care (SOC) improved MG-ADL score from baseline by 4.70 points compared with 3.25 points with placebo plus SOC over weeks 22, 23, and 24. The Food and Drug ...

Diagnosis of generalized myasthenia gravis involves clinical symptoms, serologic markers, and electrodiagnostic studies, with AChR and MuSK autoantibodies being key indicators. Differentiating ...

Credit: Shutterstock. The randomized, double-blind, placebo-controlled phase 3 study included 175 adults with generalized myasthenia gravis who were not previously treated with a complement inhibitor.

Data from the randomized MINT trial, presented at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) annual meeting, showed that the anti-CD19 monoclonal antibody ...

The MarketWatch News Department was not involved in the creation of this content. New York, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug ...

Data from the 52-week follow-up of the phase III MINT trial of inebilizumab (Uplizna) in generalized myasthenia gravis was presented at the American Association of Neuromuscular & Electrodiagnostic ...

THOUSAND OAKS, Calif., March 13, 2025 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of UPLIZNA ® ...

Please provide your email address to receive an email when new articles are posted on . Nipocalimab led to significant improvements in disease-specific metrics from baseline among patients with ...

DUBLIN--(BUSINESS WIRE)--The "Myasthenia Gravis: Epidemiology Forecast to 2028" report has been added to ResearchAndMarkets.com's offering. Myasthenia Gravis: Epidemiology Forecast to 2028 ...

New York, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen’s UPLIZNA ® (inebilizumab-cdon) for the ...